Top Liver Cirrhosis Treatment Companies

Global Liver Cirrhosis Treatment Market size was valued at USD 18.9 Billion in 2024 and is poised to grow from USD 20.11 Billion in 2025 to USD 33.03 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026–2033).

The competitive environment of the Global Liver Cirrhosis Treatment Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. The liver cirrhosis treatment market is fragmented, with several key players. In terms of market share, the market is currently dominated by a few major players. The companies currently dominating the market include Abbott Laboratories, Gilead Sciences, Novartis AG, Sanofi, Astellas Pharma, Inc. and others. 'Gilead Sciences (United States) ', 'Pfizer Inc. (United States) ', 'Merck & Co., Inc. (United States) ', 'Novartis AG (Switzerland) ', 'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Takeda Pharmaceutical Company Limited (Japan) ', 'AstraZeneca (United Kingdom) ', 'Bayer AG (Germany) ', 'Sanofi (France) ', 'AbbVie Inc. (United States) ', 'GlaxoSmithKline PLC (United Kingdom) ', 'Bristol-Myers Squibb Company (United States) ', 'Alnylam Pharmaceuticals Inc. (United States) ', 'Viking Therapeutics (United States) ', 'Galectin Therapeutics Inc. (United States) ', 'Akero Therapeutics, Inc. (United States) ', 'NGM Biopharmaceuticals, Inc. (United States) ', 'Poxel SA (France)'

Liver disease is still very common worldwide. Due to sedentary lifestyle, inactivity and especially poor diet, many people are suffering from liver disease. The aging population is getting older, and autoimmune diseases such as hepatitis and non-alcoholic fatty liver are on the rise. We can also attribute the significant increase in cases to alcohol consumption greater than. Increasing availability of therapies for liver diseases will drive the global market for treatment of liver diseases. In response to increased demand for hepatitis treatment, healthcare organizations funded the development of new drugs, devices, and treatment options, supported by biotechnology and research institutes around the world greatly led to the development of new drugs for the treatment of liver disease. Due to the growth and development, the market for treatment of liver diseases will be highly competitive and prosperous. This is expected to open lucrative opportunities for market participants and accelerate market growth.

Rising Research and Development Efforts: Increasing R&D efforts to develop new therapies and therapeutic targets for liver disease, increasing services and funding for prevention, diagnosis and treatment of liver disease, increasing liver disease awareness, if needed the need for early diagnosis and healthcare costs. Increasing aging population, increasing awareness, improving healthcare infrastructure, increasing disposable income in emerging markets and increasing advancement in surgical procedures, procedures not taken more penetration and radiology interventions further support the growth of the market.

The largest regional market. cirrhosis of the liver is common in the United States. In the U.S. saw 88,000 deaths from alcohol-related liver disease and hepatitis. Additionally, the health care system in the U.S. has 88,000 deaths from alcohol-related liver disease is also growing, contributing to the growth of the global liver cirrhosis treatment market. Furthermore, Pfizer Inc. has a strong presence in the market.